Spero Therapeutics (SPRO) Accumulated Depreciation & Amortization (2016 - 2024)
Spero Therapeutics (SPRO) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $3.6 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Accumulated Depreciation & Amortization changed 0.06% year-over-year to $3.6 million, compared with a TTM value of $3.6 million through Dec 2024, changed 0.06%, and an annual FY2024 reading of $3.6 million, changed 0.06% over the prior year.
- Accumulated Depreciation & Amortization was $3.6 million for Q4 2024 at Spero Therapeutics, roughly flat from $3.6 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $3.6 million in Q4 2024 and bottomed at $2.3 million in Q4 2020.
- Average Accumulated Depreciation & Amortization over 5 years is $3.1 million, with a median of $3.3 million recorded in 2022.
- The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 50.23% in 2020, then increased 0.06% in 2024.
- Year by year, Accumulated Depreciation & Amortization stood at $2.3 million in 2020, then grew by 26.54% to $2.9 million in 2021, then rose by 12.92% to $3.3 million in 2022, then rose by 11.25% to $3.6 million in 2023, then increased by 0.06% to $3.6 million in 2024.
- Business Quant data shows Accumulated Depreciation & Amortization for SPRO at $3.6 million in Q4 2024, $3.6 million in Q4 2023, and $3.3 million in Q4 2022.